APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Proteins for Cardiovascular Disorders Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Research

Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Research Report 2026

22 December 2025123 pages

Choose your research edition.

Industry ResearchTherapeutic Proteins for Cardiovascular Disorders Treatment Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Therapeutic Proteins for Cardiovascular Disorders Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Proteins for Cardiovascular Disorders Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Proteins for Cardiovascular Disorders Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Therapeutic Proteins for Cardiovascular Disorders Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Therapeutic Proteins for Cardiovascular Disorders Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Therapeutic Proteins for Cardiovascular Disorders Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Therapeutic Proteins for Cardiovascular Disorders Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Therapeutic Proteins for Cardiovascular Disorders Treatment include Bristol Myers Squibb, Siemens Healthineers, Amgen, Pfizer, Eli Lilly & Company, Roche, Merck, Novartis and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Therapeutic Proteins for Cardiovascular Disorders Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Therapeutic Proteins for Cardiovascular Disorders Treatment Market by Company

Bristol Myers Squibb

Siemens Healthineers

Amgen

Pfizer

Eli Lilly & Company

Roche

Merck

Novartis

Johnson & Johnson

Sanofi

Therapeutic Proteins for Cardiovascular Disorders Treatment Segment by Type

Peptide Fragments Proteins

Peptides Proteins

Monoclonal Antibodies Proteins

Therapeutic Proteins for Cardiovascular Disorders Treatment Segment by Application

Heart Failure

Arrhythmias

Myocardial Infarction

Ischemic Heart Disease

Coronary Artery Disease

Therapeutic Proteins for Cardiovascular Disorders Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Proteins for Cardiovascular Disorders Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Proteins for Cardiovascular Disorders Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Proteins for Cardiovascular Disorders Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Therapeutic Proteins for Cardiovascular Disorders Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Therapeutic Proteins for Cardiovascular Disorders Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Therapeutic Proteins for Cardiovascular Disorders Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units) of Manufacturers (2021-2026) Table 7. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Manufacturers (2021-2026) Table 8. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue of Manufacturers (2021-2026) Table 9. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Therapeutic Proteins for Cardiovascular Disorders Treatment Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Therapeutic Proteins for Cardiovascular Disorders Treatment, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Therapeutic Proteins for Cardiovascular Disorders Treatment, Product Type & Application Table 14. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Therapeutic Proteins for Cardiovascular Disorders Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Bristol Myers Squibb Company Information Table 19. Bristol Myers Squibb Business Overview Table 20. Bristol Myers Squibb Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Bristol Myers Squibb Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio Table 22. Bristol Myers Squibb Recent Developments Table 23. Siemens Healthineers Company Information Table 24. Siemens Healthineers Business Overview Table 25. Siemens Healthineers Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Siemens Healthineers Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio Table 27. Siemens Healthineers Recent Developments Table 28. Amgen Company Information Table 29. Amgen Business Overview Table 30. Amgen Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Amgen Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio Table 32. Amgen Recent Developments Table 33. Pfizer Company Information Table 34. Pfizer Business Overview Table 35. Pfizer Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Pfizer Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio Table 37. Pfizer Recent Developments Table 38. Eli Lilly & Company Company Information Table 39. Eli Lilly & Company Business Overview Table 40. Eli Lilly & Company Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Eli Lilly & Company Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio Table 42. Eli Lilly & Company Recent Developments Table 43. Roche Company Information Table 44. Roche Business Overview Table 45. Roche Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Roche Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio Table 47. Roche Recent Developments Table 48. Merck Company Information Table 49. Merck Business Overview Table 50. Merck Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Merck Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio Table 52. Merck Recent Developments Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Novartis Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio Table 57. Novartis Recent Developments Table 58. Johnson & Johnson Company Information Table 59. Johnson & Johnson Business Overview Table 60. Johnson & Johnson Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Johnson & Johnson Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio Table 62. Johnson & Johnson Recent Developments Table 63. Sanofi Company Information Table 64. Sanofi Business Overview Table 65. Sanofi Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Sanofi Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio Table 67. Sanofi Recent Developments Table 68. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 69. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Region (2021-2026) & (k units) Table 70. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Region (2021-2026) Table 71. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Region (2027-2032) & (k units) Table 72. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Region (2027-2032) Table 73. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region (2021-2026) & (US$ Million) Table 74. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Region (2021-2026) Table 75. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region (2027-2032) & (US$ Million) Table 76. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Region (2027-2032) Table 77. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2026) & (k units) Table 79. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2027-2032) & (k units) Table 80. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2027-2032) & (US$ Million) Table 82. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2026) & (k units) Table 84. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2027-2032) & (k units) Table 85. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2027-2032) & (US$ Million) Table 87. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2026) & (k units) Table 89. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2027-2032) & (k units) Table 90. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2026) & (US$ Million) Table 91. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2027-2032) & (US$ Million) Table 92. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2026) & (k units) Table 94. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2027-2032) & (k units) Table 95. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2026) & (US$ Million) Table 96. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2027-2032) & (US$ Million) Table 97. Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2026) & (k units) Table 99. Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2027-2032) & (k units) Table 100. Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2026) & (US$ Million) Table 101. Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2027-2032) & (US$ Million) Table 102. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2021-2026) & (k units) Table 103. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2027-2032) & (k units) Table 104. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Type (2021-2026) Table 105. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Type (2027-2032) Table 106. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Type (2021-2026) & (US$ Million) Table 107. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Type (2027-2032) & (US$ Million) Table 108. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Type (2021-2026) Table 109. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Type (2027-2032) Table 110. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Type (2021-2026) & (US$/unit) Table 111. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Type (2027-2032) & (US$/unit) Table 112. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2021-2026) & (k units) Table 113. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2027-2032) & (k units) Table 114. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Application (2021-2026) Table 115. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Application (2027-2032) Table 116. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Application (2021-2026) & (US$ Million) Table 117. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Application (2027-2032) & (US$ Million) Table 118. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Application (2021-2026) Table 119. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Application (2027-2032) Table 120. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Application (2021-2026) & (US$/unit) Table 121. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Application (2027-2032) & (US$/unit) Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Therapeutic Proteins for Cardiovascular Disorders Treatment Distributors List Table 125. Therapeutic Proteins for Cardiovascular Disorders Treatment Customers List Table 126. Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Trends Table 127. Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Drivers Table 128. Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Restraints Table 129. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Therapeutic Proteins for Cardiovascular Disorders Treatment Product Image Figure 5. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size (2021-2032) & (US$ Million) Figure 7. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (2021-2032) & (k units) Figure 8. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Average Price (US$/unit) & (2021-2032) Figure 9. Peptide Fragments Proteins Product Image Figure 10. Peptides Proteins Product Image Figure 11. Monoclonal Antibodies Proteins Product Image Figure 12. Heart Failure Product Image Figure 13. Arrhythmias Product Image Figure 14. Myocardial Infarction Product Image Figure 15. Ischemic Heart Disease Product Image Figure 16. Coronary Artery Disease Product Image Figure 17. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Therapeutic Proteins for Cardiovascular Disorders Treatment, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Therapeutic Proteins for Cardiovascular Disorders Treatment Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Region in 2025 Figure 23. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region in 2025 Figure 24. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country in 2025 Figure 25. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Country (2021-2032) Figure 26. North America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Country (2021-2032) Figure 27. United States Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country in 2025 Figure 31. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Country (2021-2032) Figure 32. Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Country (2021-2032) Figure 33. Germany Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country in 2025 Figure 44. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Country (2021-2032) Figure 46. China Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country in 2025 Figure 55. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Country (2021-2032) Figure 56. South America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Country (2021-2032) Figure 57. Brazil Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country in 2025 Figure 61. Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Country (2021-2032) Figure 63. Egypt Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Type (2021-2032) Figure 69. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Type (2021-2032) Figure 70. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price (US$/unit) by Type (2021-2032) Figure 71. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Application (2021-2032) Figure 72. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Application (2021-2032) Figure 73. Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price (US$/unit) by Application (2021-2032) Figure 74. Therapeutic Proteins for Cardiovascular Disorders Treatment Value Chain Figure 75. Therapeutic Proteins for Cardiovascular Disorders Treatment Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Opportunities and Challenges

Scope & coverage.

Types
  • Peptide Fragments Proteins
  • Peptides Proteins
  • Monoclonal Antibodies Proteins
Applications
  • Heart Failure
  • Arrhythmias
  • Myocardial Infarction
  • Ischemic Heart Disease
  • Coronary Artery Disease
Companies covered
  • Bristol Myers Squibb
  • Siemens Healthineers
  • Amgen
  • Pfizer
  • Eli Lilly & Company
  • Roche
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size (2021-2032)
  4. 2.2.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (2021-2032)
  5. 2.2.3 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Average Price (2021-2032)
  6. 2.3 Therapeutic Proteins for Cardiovascular Disorders Treatment by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Peptide Fragments Proteins
  9. 2.3.3 Peptides Proteins
  10. 2.3.4 Monoclonal Antibodies Proteins
  11. 2.4 Therapeutic Proteins for Cardiovascular Disorders Treatment by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Heart Failure
  14. 2.4.3 Arrhythmias
  15. 2.4.4 Myocardial Infarction
  16. 2.4.5 Ischemic Heart Disease
  17. 2.4.6 Coronary Artery Disease
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Therapeutic Proteins for Cardiovascular Disorders Treatment, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Therapeutic Proteins for Cardiovascular Disorders Treatment, Product Type & Application
  8. 3.8 Global Manufacturers of Therapeutic Proteins for Cardiovascular Disorders Treatment, Established Date
  9. 3.9 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Bristol Myers Squibb
  2. 4.1.1 Bristol Myers Squibb Company Information
  3. 4.1.2 Bristol Myers Squibb Business Overview
  4. 4.1.3 Bristol Myers Squibb Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Bristol Myers Squibb Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio
  6. 4.1.5 Bristol Myers Squibb Recent Developments
  7. 4.2 Siemens Healthineers
  8. 4.2.1 Siemens Healthineers Company Information
  9. 4.2.2 Siemens Healthineers Business Overview
  10. 4.2.3 Siemens Healthineers Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Siemens Healthineers Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio
  12. 4.2.5 Siemens Healthineers Recent Developments
  13. 4.3 Amgen
  14. 4.3.1 Amgen Company Information
  15. 4.3.2 Amgen Business Overview
  16. 4.3.3 Amgen Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Amgen Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio
  18. 4.3.5 Amgen Recent Developments
  19. 4.4 Pfizer
  20. 4.4.1 Pfizer Company Information
  21. 4.4.2 Pfizer Business Overview
  22. 4.4.3 Pfizer Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Pfizer Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio
  24. 4.4.5 Pfizer Recent Developments
  25. 4.5 Eli Lilly & Company
  26. 4.5.1 Eli Lilly & Company Company Information
  27. 4.5.2 Eli Lilly & Company Business Overview
  28. 4.5.3 Eli Lilly & Company Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Eli Lilly & Company Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio
  30. 4.5.5 Eli Lilly & Company Recent Developments
  31. 4.6 Roche
  32. 4.6.1 Roche Company Information
  33. 4.6.2 Roche Business Overview
  34. 4.6.3 Roche Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Roche Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio
  36. 4.6.5 Roche Recent Developments
  37. 4.7 Merck
  38. 4.7.1 Merck Company Information
  39. 4.7.2 Merck Business Overview
  40. 4.7.3 Merck Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Merck Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio
  42. 4.7.5 Merck Recent Developments
  43. 4.8 Novartis
  44. 4.8.1 Novartis Company Information
  45. 4.8.2 Novartis Business Overview
  46. 4.8.3 Novartis Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Novartis Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio
  48. 4.8.5 Novartis Recent Developments
  49. 4.9 Johnson & Johnson
  50. 4.9.1 Johnson & Johnson Company Information
  51. 4.9.2 Johnson & Johnson Business Overview
  52. 4.9.3 Johnson & Johnson Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Johnson & Johnson Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio
  54. 4.9.5 Johnson & Johnson Recent Developments
  55. 4.10 Sanofi
  56. 4.10.1 Sanofi Company Information
  57. 4.10.2 Sanofi Business Overview
  58. 4.10.3 Sanofi Therapeutic Proteins for Cardiovascular Disorders Treatment Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Sanofi Therapeutic Proteins for Cardiovascular Disorders Treatment Product Portfolio
  60. 4.10.5 Sanofi Recent Developments
5 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Scenario by Region
  1. 5.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Region: 2021-2032
  3. 5.2.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Region: 2021-2026
  4. 5.2.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Region: 2027-2032
  5. 5.3 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region: 2021-2032
  6. 5.3.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region: 2021-2026
  7. 5.3.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Region: 2027-2032
  8. 5.4 North America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Facts & Figures by Country
  9. 5.4.1 North America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2032)
  11. 5.4.3 North America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Market Facts & Figures by Country
  16. 5.5.1 Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2032)
  18. 5.5.3 Europe Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Facts & Figures by Country
  41. 5.7.1 South America Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2032)
  43. 5.7.3 South America Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2021-2032)
  2. 6.1.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Type (2021-2032)
  4. 6.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Type (2021-2032)
  5. 6.2.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2021-2032)
  2. 7.1.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Market Share by Application (2021-2032)
  4. 7.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue by Application (2021-2032)
  5. 7.2.1 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Therapeutic Proteins for Cardiovascular Disorders Treatment Value Chain Analysis
  2. 8.1.1 Therapeutic Proteins for Cardiovascular Disorders Treatment Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Therapeutic Proteins for Cardiovascular Disorders Treatment Production Mode & Process
  5. 8.2 Therapeutic Proteins for Cardiovascular Disorders Treatment Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Therapeutic Proteins for Cardiovascular Disorders Treatment Distributors
  8. 8.2.3 Therapeutic Proteins for Cardiovascular Disorders Treatment Customers
9 Global Therapeutic Proteins for Cardiovascular Disorders Treatment Analyzing Market Dynamics
  1. 9.1 Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Trends
  2. 9.2 Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Drivers
  3. 9.3 Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Opportunities and Challenges
  4. 9.4 Therapeutic Proteins for Cardiovascular Disorders Treatment Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst